The notices it replaced
- Reissues: PAR-21-160 NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
- 2 steps back: PAR-18-547 NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3) - Clinical Trial Required
Who won it before
11 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,969,437 in first-year total cost, median $596,109.
Most frequent study sections
- Special Emphasis Panel[ZDE1 YM (02)]3
- Special Emphasis Panel[ZDE1 YM (06)]3
- Special Emphasis Panel[ZDE1 YM (07)]2
- Special Emphasis Panel[ZDE1 CF (12)]1
- Special Emphasis Panel[ZDE1 YM (03)]1
Most frequent institutions
- UNIV OF NORTH CAROLINA CHAPEL HILL3
- CAROLINAS MEDICAL CENTER1
- CINCINNATI CHILDRENS HOSP MED CTR1
- RBHS-SCHOOL OF DENTAL MEDICINE1
- RISE THERAPEUTICS, LLC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Effectiveness of an Early Intensive Preventive Dental Program by Oncology Providers to Reduce Dental Disease and Improve Compliance in Head and Neck Cancer Patients: OraRad IPDP1UG3DE035104-01 · under PAR-21-160 | BRENNAN, MICHAEL TLALLA, RAJESH V. | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $681,331 | ZDE1 |
| 2025 | Safety and analgesic efficacy of marine lipid precursors of specialized pro-resolving mediators in adults with chronic temporomandibular pain.1UG3DE033354-01A1 · under PAR-21-160 | SANDERS, ANNE E. | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $603,502 | ZDE1 |
| 2025 | A Novel Immunological-Directed Probiotic for the Treatment of Sjögren’s Syndrome1UG3DE034134-01A1 · under PAR-21-160 | FANGER, GARY | RISE THERAPEUTICS, LLC, MD | $429,158 | ZDE1 |
| 2024 | A Phase II Randomized Assessment of Sparing Parotid Ducts via MRI Sialography for Reduced Patient Reported Xerostomia1UG3DE033389-01 · under PAR-21-160 | FRIED, DAVID V | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $357,398 | ZDE1 |
| 2022 | Randomized Trial of non-Surgical Therapy and Oral Hygiene Instruction to Reduce Risk of Infective Endocarditis1UG3DE031250-01 · under PAR-18-547 | LOCKHART, PETER B | CAROLINAS MEDICAL CENTER, NC | $660,849 | ZDE1 |
| 2022 | Photobiomodulation for the management of Temporomandibular disorder pain1UG3DE030433-01A1 · under PAR-21-160 | FILLINGIM, ROGER BRIBEIRO-DASILVA, MARGARETE C | UNIVERSITY OF FLORIDA, FL | $559,388 | ZDE1 |
| 2021 | Povidone Iodine Efficacy Study (PIES)1UG3DE030434-01 · under PAR-18-547 | KOPYCKA-KEDZIERAWSKI, DOROTA T. | UNIVERSITY OF ROCHESTER, NY | $596,109 | ZDE1 |
| 2021 | Reduction of bloodstream infections from oral organisms in pediatric stem cell transplant: a randomized, multicenter, double-blind, placebo-controlled study evaluating twice daily oral xylitol1UG3DE030401-01 · under PAR-18-547 | DANDOY, CHRISTOPHER EUGENE | CINCINNATI CHILDRENS HOSP MED CTR, OH | $490,242 | ZDE1 |
| 2021 | Intra-salivary gland autotransplantation of marrow mesenchymal stromal cells for treatment of radiation induced xerostomia1UG3DE030431-01 · under PAR-18-547 | KIMPLE, RANDALL J. | UNIVERSITY OF WISCONSIN-MADISON, WI | $311,832 | ZDE1 |
| 2020 | Phase II, proof-of-concept randomized controlled trial to evaluate dental caries preventive effects of fluoridated bottle water1UG3DE029169-01A1 · under PAR-18-547 | SLADE, GARY DOUGLAS | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $651,121 | ZDE1 |
| 2019 | Opiod Analgesic Reduction Study (OARS): Managing Acute Post-Operative Surgical Pain1UG3DE028860-01 · under PAR-18-547 | FELDMAN, CECILE | RBHS-SCHOOL OF DENTAL MEDICINE, NJ | $628,507 | ZDE1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.